Julien Rongère
General Counsel at AC IMMUNE SA
Profile
Julien Rongère is currently working as the VP-Regulatory Affairs & Quality Assurance at AC Immune SA. Previously, he worked as the Director-Regulatory Affairs at Celgene Switzerland SARL and as a Regulatory Expert at Apoxis SA. Dr. Rongère holds a graduate degree from the University of Aberdeen and a doctorate degree from the University of Lausanne.
Julien Rongère active positions
Companies | Position | Start |
---|---|---|
AC IMMUNE SA | General Counsel | 2017-06-30 |
Former positions of Julien Rongère
Companies | Position | End |
---|---|---|
Apoxis SA
Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - |
Celgene Switzerland SARL
Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland. | General Counsel | - |
Training of Julien Rongère
University of Aberdeen | Graduate Degree |
University of Lausanne | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AC IMMUNE SA | Health Technology |
Private companies | 2 |
---|---|
Apoxis SA
Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Celgene Switzerland SARL
Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Julien Rongère